Financials in USD. Standardized financial statements.
A compact view of how Tibet Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2010 | FY 2009 | FY 2008 |
|---|---|---|---|
| Revenue? | $32.36M | $23.01M | $15.58M |
| Revenue Growth? | +40.7% | +47.7% | 0.0% |
| Cost of Revenue? | $16.19M | $11.30M | $7.86M |
| Gross Profit? | $16.18M | $11.70M | $7.72M |
| Gross Margin? | +50.0% | +50.9% | +49.6% |
| Operating Expenses? | $2.86M | $2.29M | $1.63M |
| Operating Income? | $13.32M | $9.42M | $6.09M |
| EBITDA? | $14.22M | $10.30M | $6.88M |
| Income Before Tax | $0 | $0 | $0 |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income? | $13.14M | $9.24M | $5.93M |
| EPS? | $1.11 | $0.79 | $0.51 |
| Diluted EPS? | $1.11 | $0.79 | $0.51 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality